Effect of Adjuvant Chemo on Elderly Patients’ Quality of Life

Article

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC

Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC

Tim Cortese
March 8th 2025
Article

Results from the phase 3 REZOR trial show a median PFS of 19.3 months with rezivertinib vs 9.6 months with gefitinib in patients with NSCLC.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer

Russ Conroy
March 7th 2025
Article

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

Tim Cortese
March 7th 2025
Article

The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Viviana Cortlana, PGY-4;Jade Gambill, BSc;Jenna Ghazal, BSc;Kennedy Itodo;Shreevikaa Kannan, PGY-5;Yan Leyfman, MD;Chandler H. Park, MD, FACP
March 7th 2025
Article

Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.